U.S. Markets closed

Axsome Therapeutics, Inc. (AXSM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
24.46-0.29 (-1.17%)
At close: 04:00PM EDT
24.44 -0.02 (-0.08%)
After hours: 07:11PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close24.75
Bid24.01 x 1200
Ask24.67 x 1000
Day's Range23.85 - 25.32
52 Week Range19.38 - 74.10
Avg. Volume1,120,985
Market Cap921.939M
Beta (5Y Monthly)2.41
PE Ratio (TTM)N/A
EPS (TTM)-3.35
Earnings DateFeb 28, 2022 - Mar 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est81.21
  • GlobeNewswire

    Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event

    NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will host a virtual event on Tuesday, June 28, 2022 at 9:00 AM EDT to provide investors an update on Sunosi® (solriamfetol). Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in ad

  • Motley Fool

    3 Stocks That Could Double by 2025

    Here's why they chose Axsome Therapeutics (NASDAQ: AXSM), Jazz Pharmaceuticals (NASDAQ: JAZZ), and Twist Bioscience (NASDAQ: TWST). Prosper Junior Bakiny (Axsome Therapeutics): Investors intent on doubling their money by 2025 might benefit from looking at stocks that seem wildly undervalued and could experience multiple catalysts in the next couple of years. Axsome Therapeutics lagged the market in recent months, primarily because of regulatory roadblocks.

  • Motley Fool

    2 Top Biotech Stocks Ready for Bull Runs

    Let's look at two stocks that could rebound from their recent woes in the market: Axsome Therapeutics (NASDAQ: AXSM) and CRISPR Therapeutics (NASDAQ: CRSP). Few things can wreak more havoc on biotech companies than regulatory rejections for their leading pipeline candidates. The company's shares have been hammered over the past year because it failed to earn regulatory approval for its two leading products.